Literature DB >> 7964463

Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras.

M Tary-Lehmann1, P V Lehmann, D Schols, M G Roncarolo, A Saxon.   

Abstract

Injecting human peripheral blood mononuclear cells into severe combined immunodeficient (SCID) mice results in long-term engraftment of human lymphocytes, of which > 98% are phenotypically mature, activated T cells. Here we have characterized the human T cells that populate such hu-PBL-SCID chimeras. We report that these human T cells do not mobilize Ca2+ after CD3 stimulation, i.e., their T cell receptor (TCR)-mediated signal transduction is deficient. Chimera-derived human T cells do not secrete lymphokines or undergo blastogenesis after CD3 stimulation, but proliferate in response to interleukin 2 (IL-2), defining the chimera derived human T cells as anergic. Anergy was seen in both the CD4+ and the CD8+ subpopulations. We established human T cell lines from chimeras. These T cells retained their anergic state for 1-2 mo in culture, after which they simultaneously regained the ability to mobilize Ca2+, secrete lymphokines, and to undergo blastogenesis following stimulation via the TCR. Once regaining proliferative responsiveness to CD3 stimulation, these CD4+ T cell lines displayed anti-SCID mouse reactivity and showed no specificity for recall antigens. All CD3-responsive CD4+ T cell clones obtained from such lines were SCID mouse specific, recognizing native major histocompatibility complex class II products on the murine cells. In contrast, chimera-derived human CD8+ cell lines and clones did not display detectable anti-mouse reactivity. The data show that the human T cell system in long term hu-PBL-SCID chimeras is nonfunctional due to both anergy and the limitation of the CD4+ repertoire to xenoreactive clones. The data suggest that long-term hu-PBL-SCID chimerism represents an atypical graft-versus-host reaction in which the human effector T cells become anergic in the murine environment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964463      PMCID: PMC2191753          DOI: 10.1084/jem.180.5.1817

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

Review 1.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Authors:  D L Mueller; M K Jenkins; R H Schwartz
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Induction of graft versus host-associated immunodeficiency by CD4+ T cell clones.

Authors:  M Tary-Lehmann; A G Rolink; P V Lehmann; Z A Nagy; U Hurtenbach
Journal:  J Immunol       Date:  1990-10-01       Impact factor: 5.422

3.  Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity.

Authors:  S Webb; C Morris; J Sprent
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

4.  Engraftment of immune-deficient mice with human hematopoietic stem cells.

Authors:  S Kamel-Reid; J E Dick
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

Review 5.  Peripheral T-cell reactivity to bacterial superantigens in vivo: the response/anergy paradox.

Authors:  H R MacDonald; R K Lees; S Baschieri; T Herrmann; A R Lussow
Journal:  Immunol Rev       Date:  1993-06       Impact factor: 12.988

6.  Single step separation of human T and B cells using AET treated srbc rosettes.

Authors:  A Saxon; J Feldhaus; R A Robins
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

7.  Acute lethal graft-versus-host reaction induced by major histocompatibility complex class II-reactive T helper cell clones.

Authors:  P V Lehmann; G Schumm; D Moon; U Hurtenbach; F Falcioni; S Muller; Z A Nagy
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

8.  Transfer of a functional human immune system to mice with severe combined immunodeficiency.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

9.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

10.  Long-term human hematopoiesis in the SCID-hu mouse.

Authors:  R Namikawa; K N Weilbaecher; H Kaneshima; E J Yee; J M McCune
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  30 in total

1.  A model for personalized in vivo analysis of human immune responsiveness.

Authors:  Hannes Kalscheuer; Nichole Danzl; Takashi Onoe; Ted Faust; Robert Winchester; Robin Goland; Ellen Greenberg; Thomas R Spitzer; David G Savage; Hiroyuki Tahara; Goda Choi; Yong-Guang Yang; Megan Sykes
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

2.  Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.

Authors:  L Covassin; J Laning; R Abdi; D L Langevin; N E Phillips; L D Shultz; M A Brehm
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

3.  T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells.

Authors:  P Rizza; S M Santini; M A Logozzi; C Lapenta; P Sestili; G Gherardi; R Lande; M Spada; S Parlato; F Belardelli; S Fais
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

5.  Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Vladimir Vrbanac; Radiana Trifonova; Michael A Brehm; Adi Gilboa-Geffen; Serah Tanno; Dale L Greiner; Andrew D Luster; Andrew M Tager; Judy Lieberman
Journal:  Mol Ther       Date:  2013-04-30       Impact factor: 11.454

6.  Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells.

Authors:  C Gysemans; M Waer; J Laureys; J Depovere; D Pipeleers; R Bouillon; C Mathieu
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

7.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

8.  Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.

Authors:  Steve Pino; Michael A Brehm; Laurence Covassin-Barberis; Marie King; Bruce Gott; Thomas H Chase; Jennifer Wagner; Lisa Burzenski; Oded Foreman; Dale L Greiner; Leonard D Shultz
Journal:  Methods Mol Biol       Date:  2010

9.  Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.

Authors:  A Tsicopoulos; J Pestel; O Fahy; H Vorng; F Vandenbusche; H Porte; L Eraldi; A Wurtz; H Akoum; Q Hamid; B Wallaert; A B Tonnel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo.

Authors:  Qi Jiang; Liguo Zhang; Rui Wang; Jerry Jeffrey; Michael L Washburn; Dedeke Brouwer; Selena Barbour; Grigoriy I Kovalev; Derya Unutmaz; Lishan Su
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.